Victory Capital Management’s Amphastar Pharmaceuticals AMPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.02M | Sell |
149,612
-100,005
| -40% | -$2.02M | ﹤0.01% | 1517 |
|
|
2026
Q1 | $4.89M | Sell |
249,617
-55,544
| -18% | -$1.36M | ﹤0.01% | 1338 |
|
|
2025
Q4 | $8.17M | Buy |
305,161
+93,361
| +44% | +$2.4M | ﹤0.01% | 1115 |
|
|
2025
Q3 | $5.64M | Buy |
211,800
+134,938
| +176% | +$3.48M | ﹤0.01% | 1307 |
|
|
2025
Q2 | $1.76M | Sell |
76,862
-4,225
| -5% | -$105K | ﹤0.01% | 1629 |
|
|
2025
Q1 | $2.35M | Buy |
81,087
+17,700
| +28% | +$565K | ﹤0.01% | 1485 |
|
|
2024
Q4 | $2.35M | Sell |
63,387
-155,144
| -71% | -$7.09M | ﹤0.01% | 1452 |
|
|
2024
Q3 | $10.6M | Buy |
218,531
+21,530
| +11% | +$945K | 0.01% | 1089 |
|
|
2024
Q2 | $7.88M | Sell |
197,001
-15,685
| -7% | -$650K | 0.01% | 1146 |
|
|
2024
Q1 | $9.34M | Sell |
212,686
-24,788
| -10% | -$1.28M | 0.01% | 1081 |
|
|
2023
Q4 | $14.7M | Buy |
237,474
+213,014
| +871% | +$11.2M | 0.02% | 897 |
|
|
2023
Q3 | $1.12M | Sell |
24,460
-4,476
| -15% | -$244K | ﹤0.01% | 1593 |
|
|
2023
Q2 | $1.66M | Sell |
28,936
-14,802
| -34% | -$656K | ﹤0.01% | 1455 |
|
|
2023
Q1 | $1.64M | Buy |
43,738
+6,646
| +18% | +$218K | ﹤0.01% | 1463 |
|
|
2022
Q4 | $1.04M | Buy |
37,092
+665
| +2% | +$19.3K | ﹤0.01% | 1721 |
|
|
2022
Q3 | $1.02M | Sell |
36,427
-8,323
| -19% | -$272K | ﹤0.01% | 1724 |
|
|
2022
Q2 | $1.56M | Sell |
44,750
-17,949
| -29% | -$641K | ﹤0.01% | 1554 |
|
|
2022
Q1 | $2.22M | Sell |
62,699
-8,904
| -12% | -$252K | ﹤0.01% | 1466 |
|
|
2021
Q4 | $1.67M | Buy |
71,603
+25,073
| +54% | +$513K | ﹤0.01% | 1615 |
|
|
2021
Q3 | $885K | Buy |
46,530
+26,957
| +138% | +$528K | ﹤0.01% | 1913 |
|
|
2021
Q2 | $395K | Buy |
19,573
+327
| +2% | +$6.16K | ﹤0.01% | 2315 |
|
|
2021
Q1 | $353K | Buy |
19,246
+5,674
| +42% | +$106K | ﹤0.01% | 2348 |
|
|
2020
Q4 | $273K | Buy |
13,572
+1,050
| +8% | +$20.4K | ﹤0.01% | 2310 |
|
|
2020
Q3 | $235K | Sell |
12,522
-688
| -5% | -$13.9K | ﹤0.01% | 2245 |
|
|
2020
Q2 | $297K | Sell |
13,210
-13,644
| -51% | -$250K | ﹤0.01% | 2183 |
|
|
2020
Q1 | $399K | Sell |
26,854
-12,300
| -31% | -$214K | ﹤0.01% | 1921 |
|
|
2019
Q4 | $755K | Buy |
39,154
+20,000
| +104% | +$384K | ﹤0.01% | 1833 |
|
|
2019
Q3 | $380K | Buy |
+19,154
| New | +$399K | ﹤0.01% | 1989 |
|
|
2017
Q3 | – | Sell |
-5,611
| Closed | -$100K | – | 1808 |
|
|
2017
Q2 | $100K | Buy |
5,611
+842
| +18% | +$13.4K | ﹤0.01% | 1677 |
|
|
2017
Q1 | $69K | Buy |
+4,769
| New | +$75K | ﹤0.01% | 1706 |
|
|
2016
Q3 | – | Sell |
-1,557
| Closed | -$25K | – | 1778 |
|
|
2016
Q2 | $25K | Buy |
1,557
+202
| +15% | +$2.85K | ﹤0.01% | 1588 |
|
|
2016
Q1 | $16K | Buy |
1,355
+106
| +8% | +$1.25K | ﹤0.01% | 1626 |
|
|
2015
Q4 | $18K | Buy |
1,249
+67
| +6% | +$885 | ﹤0.01% | 1652 |
|
|
2015
Q3 | $14K | Buy |
1,182
+105
| +10% | +$1.57K | ﹤0.01% | 1594 |
|
|
2015
Q2 | $19K | Buy |
+1,077
| New | +$16.8K | ﹤0.01% | 1596 |
|
Other funds holding AMPH
Victory Capital Management's AMPH Position: Q2 2026 in Review
Victory Capital Management reduced its Amphastar Pharmaceuticals (AMPH) stake by 40% in Q2 2026, selling an estimated $2.02M and leaving 149,612 shares worth $3.02M. The position accounts for ﹤0.01% of the portfolio, ranked #1517.
Victory Capital Management first reported a position in AMPH in Q2 2015 and has held it in 35 quarters since. The position peaked at $14.7M in Q4 2023. 212 funds tracked by Wall St. Rank hold AMPH as of Q2 2026.
- Victory Capital Management held 149,612 shares of Amphastar Pharmaceuticals worth $3.02M as of Q2 2026.
- Victory Capital Management sold 100,005 Amphastar Pharmaceuticals shares in Q2 2026, an estimated $2.02M.
- Amphastar Pharmaceuticals made up ﹤0.01% of Victory Capital Management's portfolio in Q2 2026, its #1517 holding.
- Victory Capital Management first reported a position in Amphastar Pharmaceuticals in Q2 2015 and has held it in 35 quarters since.
- Victory Capital Management's Amphastar Pharmaceuticals position peaked at $14.7M in Q4 2023.
- 212 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q2 2026.
Based on Victory Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.